“Lisa, Ed, and Allan bring a wealth of knowledge and experience to Establishment Labs that will complement our current Board and Management team,” said Juan Jose Chacon Quiros, CEO of Establishment Labs. “Their unique combination of skills and talents will help us achieve our goal of becoming the market leader in breast implants, both in innovation and best of class products.”
"With an unparalleled focus on the unmet needs of women around the world, and a systematic approach to product design, Establishment Labs has developed a transformative technology in the field of breast implants. I am very excited to be a part of this extraordinary Board of Directors,” said Lisa Colleran. Ms. Colleran served as President of LifeCell Corporation between 2008 and 2013, and led sell side activities for two major transactions of LifeCell, including the acquisition by KCI for $1.7 billion.
Ed Schutter is a thirty-year veteran of the pharmaceutical industry, currently the President and CEO of Arbor Pharmaceuticals. Prior to Arbor, Ed served as President of Sciele Pharmaceuticals which was sold to Shionogi & Co. Ltd. in 2008 for $1.3 billion. Of his appointment to the board, Ed Schutter said, “Establishment Labs is bringing innovation to an industry in great need of a new approach. With the best medical and scientific minds of 2015, I am confident we can create better products and solutions than the state-of-the-art from the 1990s. I am excited to be both an Investor and a Board Member of a company that can make such an impact.”
Dr. Weinstein is an independent entrepreneur focused on intellectual property in the life sciences, as well as a Board-certified immunologist and, like both Mr. Schutter and Ms. Colleran, creates a true multidisciplinary approach to building a world-class organization. Dr. Weinstein commented, “Establishment Labs brings together a world-renowned team committed to innovation and excellence. I’m pleased to join its Board of Directors, as physicians worldwide recognize the distinction of Motiva products and services in this critical field.”